Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, has appointed Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer. With more than 30 years of healthcare experience, Taylor will lead essential aspects of legal, compliance and privacy efforts, and will report to Biocept President and CEO Michael Nall.

“Darrell’s strong leadership background and his combination of diagnostics industry experience and legal expertise makes him an excellent fit for Biocept,” said Nall. “Darrell is a key addition to our executive team and will support our initiatives and goals, as we continue to advance our core oncology business and implement our COVID-19 testing program. We are pleased to welcome Darrell to the team.”

Taylor brings extensive healthcare and leadership experience, including over 20 years as a healthcare attorney honing his skills at the global law firm DLA Piper. He has provided legal, regulatory and compliance counsel to leading biopharmaceutical companies as well as numerous biotech start-ups. Most recently, Taylor served as Chief Compliance Officer for Precision Diagnostics, and its CLIA-certified and CAP-accredited clinical laboratory. Prior to embarking on his law career, Taylor built a strong healthcare foundation serving in leadership positions in clinical laboratory operations with Lab Corp of America and various hospitals, developing and implementing regulatory compliance programs.

“I am excited to join the Biocept team and support company efforts focused on developing innovative diagnostic solutions for patients with metastatic cancers, while providing vital testing services during the COVID-19 pandemic,” Taylor said. “I look forward to working across the organization from a legal and compliance perspective, as we continue commercializing CNSide™, our proprietary assay that uses cerebrospinal fluid to identify, characterize and monitor tumors that have metastasized to the central nervous system.”

About Biocept

Biocept, Inc., develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information to aid in the diagnosis, treatment and monitoring of patients with cancer. In addition to its broad portfolio of blood-based liquid biopsy tests, the company has developed the CNSide™ cerebrospinal fluid assay, designed to diagnose cancer that has metastasized to the central nervous system. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.

Forward-Looking Statements Disclaimer

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "will," "designed," "look forward to" and "potential" or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding the potential of CNSide to diagnose cancer that has metastasized to the central nervous system and the ability of Biocept’s molecular diagnostic assays to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risks and uncertainties, including the risk that our products and services may not perform as expected. These and other risks are described in greater detail under the "Risk Factors" heading of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission (SEC) on November 15, 2021. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220210005392/en/